BioSpace News Archive

Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, announced that Doug Drysdale, Chief Executive Officer, will be presenting at the Benzinga Global Small Cap Conference as follows:

Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA), formerly Debut Diamonds Inc. (CSE:DDI), announces the successful closing of its previously announced reverse takeover (“RTO”) of Debut Diamonds Inc. (“Debut”) by Wesana Health Inc.

Select Medical Holdings Corporation announced results for its first quarter ended March 31, 2021 and the declaration of a cash dividend.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), announced today that it will report financial results and highlights for the quarter ended March 31, 2021

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three months ended March 31, 2021 and provided a business update.

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced financial results for the first quarter that ended March 31, 2021, and provided a business update.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the Bank of America Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021 at 8:45 a.m. ET.

New Gladstone research points to a mechanism driven by a protein associated with a higher risk of developing the disease

Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd. (KOSDAQ:89140), has selected its first technological investment target to expand its new bio business.

Johnson & Johnson Vision*, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies**, today announced the U.S. Food and Drug Administration (FDA) approval of TECNIS Synergy™ and TECNIS Synergy™ Toric II IOLs, and the Health Canada approval of TECNIS Synergy™ Toric II IOLs.